 GAITHERSBURG, Md., June 03, 2022 GLOBE NEWSWIRE -- Altimmune, Inc. Nasdaq: ALT, a clinical-stage biopharmaceutical company, today announced that members of the Companys management team will participate at the following investor conferences in June 2022: 